HS
DSGN icon

HighVista Strategies’s Design Therapeutics DSGN Stock Holding History

HighVista Strategies’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-38,152
Closed -$638K – 111
2022
Q3 		$638K Buy
+38,152
New +$759K 0.36% 73

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HighVista Strategies's DSGN Position: Q4 2022 in Review

HighVista Strategies sold out of Design Therapeutics (DSGN) in Q4 2022, closing a stake of 38,152 shares — an estimated $638K sold.

HighVista Strategies first reported a position in DSGN in Q3 2022 and held it in 1 quarter. The position peaked at $638K in Q3 2022. 83 funds tracked by Wall St. Rank hold DSGN as of Q4 2022.

  • HighVista Strategies reported no remaining Design Therapeutics position as of Q4 2022 after selling out during the quarter.
  • HighVista Strategies sold 38,152 Design Therapeutics shares in Q4 2022, an estimated $638K.
  • HighVista Strategies first reported a position in Design Therapeutics in Q3 2022 and held it in 1 quarter.
  • HighVista Strategies's Design Therapeutics position peaked at $638K in Q3 2022.
  • 83 funds tracked by Wall St. Rank held Design Therapeutics as of Q4 2022.

Based on HighVista Strategies's 13F filing for Q4 2022, filed 14 Feb 2023.